gefitinib has been researched along with nintedanib in 8 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (nintedanib) | Trials (nintedanib) | Recent Studies (post-2010) (nintedanib) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 846 | 133 | 801 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bantscheff, M; Bergamini, G; Gohlke, B; Gupta, V; Handa, H; Heinzlmeir, S; Helm, D; Klaeger, S; Kuster, B; Médard, G; Perrin, J; Preissner, R; Qiao, H; Savitski, MM | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Chen, L; Li, Y; Liu, K; Ma, T; Ma, X; Sun, H; Sun, X; Wang, C; Zheng, X; Zhu, Y | 1 |
| Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
| Chiba, M; Gemma, A; Kubota, K; Matsumoto, M; Miyanaga, A; Nishijima, N; Noro, R; Seike, M; Soeno, C; Sugano, T | 1 |
| Branca, RM; Cao, X; Johansson, HJ; Minozada, R; Orre, LM; Seashore-Ludlow, B; Zhou Tran, Y | 1 |
1 review(s) available for gefitinib and nintedanib
| Article | Year |
|---|---|
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
7 other study(ies) available for gefitinib and nintedanib
| Article | Year |
|---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors.
Topics: Benzocycloheptenes; Cell Line, Tumor; Ferrochelatase; Heme; Humans; Imidazoles; Indoles; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Proteomics; Pyrazines; Pyridines; Quinolines; Sulfonamides; Vemurafenib | 2016 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Dose-Response Relationship, Drug; Epithelial Cells; Female; Humans; Idiopathic Pulmonary Fibrosis; Janus Kinase 3; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship | 2020 |
miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Profiling; Humans; Indoles; Inhibitory Concentration 50; Lung Neoplasms; MicroRNAs; Phenotype; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Fibroblast Growth Factor; Receptors, Vascular Endothelial Growth Factor; Zinc Finger E-box-Binding Homeobox 1 | 2016 |
Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, Liquid; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Silencing; Humans; Indoles; Lung Neoplasms; Protein Kinase Inhibitors; Proteome; Proto-Oncogene Proteins c-bcl-6; Pyrimidines; RNA, Small Interfering; Signal Transduction; Tandem Mass Spectrometry; Up-Regulation | 2020 |